1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Relapsing-remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) Ocrelizumab (US), Ocrelizumab (EU), ABP 692 - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Active not recruiting | Amgen | 152 | 2025-01-13 | 2026-09-22 |
Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Multiple Sclerosis (1) · Nervous System Diseases (1)
ocrelizumab (1)
Amgen (1)
Belgium (1) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1) · Italy (1) · Lithuania (1) · Poland (1) · Romania (1) · Serbia (1) · Slovakia (1)